Longitudinal Evaluation of Donor-Derived Cellfree DNA in Pediatric Kidney Transplantation.

ABSTRACT:

Background and objectives

Donor-derived cellfree DNA (cfDNA) is a less-invasive marker of allograft injury compared with kidney biopsy. However, donor-derived cfDNA has not yet been extensively tested in children, where the test may have different characteristics.

Design, setting, participants, & measurements

We assayed donor-derived cfDNA (AlloSure; CareDx) from 290 stored plasma samples from a prospective biobank at our center, collected from 57 children monthly in the first year postkidney transplant between January 2013 and December 2019. We assessed the kinetic changes in donor-derived cfDNA levels within the first year post-transplant. We analyzed donor-derived cfDNA levels for associations with biopsy-proven acute rejection using area under the receiver operating char

SUBMITTER: Dandamudi R 

PROVIDER: S-EPMC9718036 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature